FDA — authorised 14 October 2011
- Application: NDA021825
- Marketing authorisation holder: CHIESI
- Local brand name: FERRIPROX
- Indication: TABLET — ORAL
- Status: approved
🇺🇸 Ferriprox in United States
FDA authorised Ferriprox on 14 October 2011
Marketing authorisations
FDA — authorised 14 October 2011
- Marketing authorisation holder: APOPHARMA INC
- Status: approved
FDA — authorised 9 September 2015
- Application: NDA208030
- Marketing authorisation holder: CHIESI
- Local brand name: FERRIPROX
- Indication: SOLUTION — ORAL
- Status: approved
FDA — authorised 8 February 2019
- Application: ANDA208800
- Marketing authorisation holder: TARO
- Local brand name: DEFERIPRONE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 19 May 2020
- Application: NDA212269
- Marketing authorisation holder: CHIESI
- Local brand name: FERRIPROX
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 29 March 2021
- Application: ANDA213239
- Marketing authorisation holder: HIKMA
- Local brand name: DEFERIPRONE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 11 December 2025
- Application: ANDA220132
- Marketing authorisation holder: SENORES PHARMS
- Local brand name: DEFERIPRONE
- Indication: TABLET — ORAL
- Status: approved
Ferriprox in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Other approved in United States
Frequently asked questions
Is Ferriprox approved in United States?
Yes. FDA authorised it on 14 October 2011; FDA authorised it on 14 October 2011; FDA authorised it on 9 September 2015.
Who is the marketing authorisation holder for Ferriprox in United States?
CHIESI holds the US marketing authorisation.